Note 2 - Liquidity	6 Months Ended
Jun. 30, 2017
Notes to Financial Statements
Liquidity and Going Concern [Text Block]	NOTE 2 - LIQUIDITY The Company continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of $1,108,945 and $1,264,273 for the six months ended June 30, 2017 and 2016, respectively. The Company has incurred losses since inception resulting in an accumulated deficit of $9,691,068 as of June 30, 2017. The Company anticipates further losses in the development of its business. The Company had a net working capital of $1,875,610 at June 30, 2017. Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the third quarter of 2018. Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the third quarter of 2018.

NOTE

- LIQUIDITY

The Company continually projects anticipated cash requirements, predominantly from the ongoing funding requirements of our neuropeptide drug development program. The majority of these expenses relate to paying external vendors such as Contract Research Organizations (CROs) and peptide synthesizer companies. They could also include business combinations, capital expenditures, and new drug development working capital requirements. As shown in the accompanying consolidated condensed financial statements, the Company incurred a net loss of

$1,108,945

and

$1,264,273

for the

six

months ended

June 30, 2017

and

2016,

respectively. The Company has incurred losses since inception resulting in an accumulated deficit of

$9,691,068

as of

June 30, 2017.

The Company anticipates further losses in the development of its business. The Company had a net working capital of

$1,875,610

June 30, 2017.

Based on its current forecast and budget, Management believes that its cash resources will be sufficient to fund its operations at least until the

third

quarter of

2018.

Absent generation of sufficient revenue from the execution of the Company’s business plan, it will need to obtain debt or equity financing by the

third

quarter of

2018.